Trials / Unknown
UnknownNCT04390685
Prevention of Breast Cancer-related Lymphedma With Tacrolimus
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Odense University Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Tacrolimus ointment may prevent lymphedema by inhibition of CD4+T cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus ointment | Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection |
Timeline
- Start date
- 2020-02-26
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2020-05-15
- Last updated
- 2021-06-25
Locations
3 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04390685. Inclusion in this directory is not an endorsement.